Pfizer’s Oral COVID-19 Pill Paxlovid Tops Merck’s Molnupiravir
Pfizer reported its protease inhibitor Paxlovid showed an 89% risk reduction for hospitalization and death compared to placebo in interim results of a Phase II/III trial. The pharma now is seeking a quick EUA in the US.
You may also be interested in...
David Peacock, President, Asia Pacific, MSD tells Scrip how Lagevrio has gained dominance in certain parts of the world, though Paxlovid may have received the ‘lion’s share’ of public attention.
The company announced updated results from a standard-risk study, which it will include in its overall new drug application, but whether Paxlovid will see approval or uptake in that group is another question.
Group’s final report said evidence was inadequate to demonstrate a net health benefit versus symptomatic care for Lagevrio, a drug that has already taken a back seat to Pfizer’s Paxlovid.